The effects of hexetidine (Oraldene) on the adherence of Candida albicans to human buccal epithelial cells in vitro and ex vivo and on in vitro morphogenesis

This study reports the effects of hexetidine (Oraldene) on two virulence attributes of Candida albicans, namely, in vitro and ex vivo adherence of yeast cells to buccal epithelial cells (BEC) and in vitro morphogenesis. The effects of hexetidine treatment of either yeast cells (stationary and expone...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmaceutical research 1997-12, Vol.14 (12), p.1765-1771
Hauptverfasser: JONES, D. S, MCGOVERN, J. G, WOOLFSON, A. D, GERMAN, S. P
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1771
container_issue 12
container_start_page 1765
container_title Pharmaceutical research
container_volume 14
creator JONES, D. S
MCGOVERN, J. G
WOOLFSON, A. D
GERMAN, S. P
description This study reports the effects of hexetidine (Oraldene) on two virulence attributes of Candida albicans, namely, in vitro and ex vivo adherence of yeast cells to buccal epithelial cells (BEC) and in vitro morphogenesis. The effects of hexetidine treatment of either yeast cells (stationary and exponential phases) or BEC on Candidal adherence, in terms of viable and non-viable adherent yeast cells, were evaluated using an acridine orange stain in conjunction with fluorescence microscopy. Ex vivo anti-adherence effects were determined by rinsing BEC in vivo with hexetidine (0.1%), removal of BEC after defined periods and inclusion in the adherence assay. The effects of hexetidine on morphogenesis were evaluated using light microscopy. Yeast cell viability following exposure to a range of concentration of hexetidine (0.005-0.1% v/v) for defined periods was determined following serial dilution and enumeration on solid media. Treatment of stationary and exponential phase yeast cells or BEC with hexetidine (0.1%) for a range of times (10-300 s) or, alternatively, with a range of concentrations of hexetidine (0.005-0.1%) for a fixed time (30s) significantly decreased the resultant Candidal/ epithelial adhesion. No correlations were observed between reduced adherence and either time of treatment or hexetidine concentration. In vivo treatment of BEC with hexetidine (0.1%) for 30s resulted in prolonged and significant reductions in the ex vivo adherence of both viable and non-viable yeast cells for periods of up to (and including) four hours post-rinsing. Treatment of C. albicans blastospores with hexetidine (0.05, 0.1% v/v) for 10s and 30s totally inhibited Candida morphogenesis, whereas treatment with lower antiseptic concentrations significantly reduced the extent of Candida morphogenesis and the rate of hyphal development. The effects of hexetidine on yeast cell viability were both concentration and time-dependent. The reduced adherence of C. albicans to BEC and the modification or inhibition of morphogenesis following exposure to hexetidine suggests a clinical role for hexetidine in the prophylaxis of both superficial candidosis and the systemic complications resulting from invasion of sub-epithelial tissue.
doi_str_mv 10.1023/A:1012140131757
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_79537612</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>516535521</sourcerecordid><originalsourceid>FETCH-LOGICAL-c308t-3bd5611865a3f1c825d14d0fcbdbea82a113b5c227e560f526ce4fa31ec78d0d3</originalsourceid><addsrcrecordid>eNpdkM9rFTEQx4NY6mv17EkIIsUeVjP5uc9beagtFHqp4G3JJrNuym7yTHZL_WP8X03powdP8x2-n5nvMIS8BfYJGBefL74AAw6SgQCjzAuyAWVEs2Xy50uyYYbLpjUSXpGTUu4YYy1s5TE53kolmNYb8vd2RIrDgG4pNA10xAdcgg8R6cebbCePEc9pinSpnPUjZowOH8mdjT54S-3UB2djoUui4zrbSPvVOTtR3Ic6NIUqHU5ToSHS-7DkROskxYfa3D_puv7Zm1Pej-lXjS2hvCZHg50KvjnUU_Lj29fb3WVzffP9andx3TjB2qURvVcaoNXKigFcy5UH6dnget-jbbkFEL1ynBtUmg2Ka4dysALQmdYzL07J2dPefU6_VyxLN4fyeLSNmNbSma0SRgOv4Pv_wLu05lhv6zjnWmkhTYXeHaC1n9F3-xxmm_90h6dX_8PBt6U-asg2ulCeMQ5gZA38BxfRkag</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>222656347</pqid></control><display><type>article</type><title>The effects of hexetidine (Oraldene) on the adherence of Candida albicans to human buccal epithelial cells in vitro and ex vivo and on in vitro morphogenesis</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>JONES, D. S ; MCGOVERN, J. G ; WOOLFSON, A. D ; GERMAN, S. P</creator><creatorcontrib>JONES, D. S ; MCGOVERN, J. G ; WOOLFSON, A. D ; GERMAN, S. P</creatorcontrib><description>This study reports the effects of hexetidine (Oraldene) on two virulence attributes of Candida albicans, namely, in vitro and ex vivo adherence of yeast cells to buccal epithelial cells (BEC) and in vitro morphogenesis. The effects of hexetidine treatment of either yeast cells (stationary and exponential phases) or BEC on Candidal adherence, in terms of viable and non-viable adherent yeast cells, were evaluated using an acridine orange stain in conjunction with fluorescence microscopy. Ex vivo anti-adherence effects were determined by rinsing BEC in vivo with hexetidine (0.1%), removal of BEC after defined periods and inclusion in the adherence assay. The effects of hexetidine on morphogenesis were evaluated using light microscopy. Yeast cell viability following exposure to a range of concentration of hexetidine (0.005-0.1% v/v) for defined periods was determined following serial dilution and enumeration on solid media. Treatment of stationary and exponential phase yeast cells or BEC with hexetidine (0.1%) for a range of times (10-300 s) or, alternatively, with a range of concentrations of hexetidine (0.005-0.1%) for a fixed time (30s) significantly decreased the resultant Candidal/ epithelial adhesion. No correlations were observed between reduced adherence and either time of treatment or hexetidine concentration. In vivo treatment of BEC with hexetidine (0.1%) for 30s resulted in prolonged and significant reductions in the ex vivo adherence of both viable and non-viable yeast cells for periods of up to (and including) four hours post-rinsing. Treatment of C. albicans blastospores with hexetidine (0.05, 0.1% v/v) for 10s and 30s totally inhibited Candida morphogenesis, whereas treatment with lower antiseptic concentrations significantly reduced the extent of Candida morphogenesis and the rate of hyphal development. The effects of hexetidine on yeast cell viability were both concentration and time-dependent. The reduced adherence of C. albicans to BEC and the modification or inhibition of morphogenesis following exposure to hexetidine suggests a clinical role for hexetidine in the prophylaxis of both superficial candidosis and the systemic complications resulting from invasion of sub-epithelial tissue.</description><identifier>ISSN: 0724-8741</identifier><identifier>EISSN: 1573-904X</identifier><identifier>DOI: 10.1023/A:1012140131757</identifier><identifier>PMID: 9453066</identifier><identifier>CODEN: PHREEB</identifier><language>eng</language><publisher>New York, NY: Springer</publisher><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antifungal agents ; Antifungal Agents - pharmacology ; Biological and medical sciences ; Candida albicans - drug effects ; Candida albicans - physiology ; Cheek ; Epithelial Cells - drug effects ; Epithelial Cells - microbiology ; Female ; Hexetidine - pharmacology ; Humans ; In Vitro Techniques ; Male ; Medical sciences ; Morphogenesis ; Mouth Mucosa - drug effects ; Mouth Mucosa - microbiology ; Pharmacology. Drug treatments</subject><ispartof>Pharmaceutical research, 1997-12, Vol.14 (12), p.1765-1771</ispartof><rights>1998 INIST-CNRS</rights><rights>Copyright Kluwer Academic Publishers Dec 1997</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c308t-3bd5611865a3f1c825d14d0fcbdbea82a113b5c227e560f526ce4fa31ec78d0d3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2117495$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9453066$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>JONES, D. S</creatorcontrib><creatorcontrib>MCGOVERN, J. G</creatorcontrib><creatorcontrib>WOOLFSON, A. D</creatorcontrib><creatorcontrib>GERMAN, S. P</creatorcontrib><title>The effects of hexetidine (Oraldene) on the adherence of Candida albicans to human buccal epithelial cells in vitro and ex vivo and on in vitro morphogenesis</title><title>Pharmaceutical research</title><addtitle>Pharm Res</addtitle><description>This study reports the effects of hexetidine (Oraldene) on two virulence attributes of Candida albicans, namely, in vitro and ex vivo adherence of yeast cells to buccal epithelial cells (BEC) and in vitro morphogenesis. The effects of hexetidine treatment of either yeast cells (stationary and exponential phases) or BEC on Candidal adherence, in terms of viable and non-viable adherent yeast cells, were evaluated using an acridine orange stain in conjunction with fluorescence microscopy. Ex vivo anti-adherence effects were determined by rinsing BEC in vivo with hexetidine (0.1%), removal of BEC after defined periods and inclusion in the adherence assay. The effects of hexetidine on morphogenesis were evaluated using light microscopy. Yeast cell viability following exposure to a range of concentration of hexetidine (0.005-0.1% v/v) for defined periods was determined following serial dilution and enumeration on solid media. Treatment of stationary and exponential phase yeast cells or BEC with hexetidine (0.1%) for a range of times (10-300 s) or, alternatively, with a range of concentrations of hexetidine (0.005-0.1%) for a fixed time (30s) significantly decreased the resultant Candidal/ epithelial adhesion. No correlations were observed between reduced adherence and either time of treatment or hexetidine concentration. In vivo treatment of BEC with hexetidine (0.1%) for 30s resulted in prolonged and significant reductions in the ex vivo adherence of both viable and non-viable yeast cells for periods of up to (and including) four hours post-rinsing. Treatment of C. albicans blastospores with hexetidine (0.05, 0.1% v/v) for 10s and 30s totally inhibited Candida morphogenesis, whereas treatment with lower antiseptic concentrations significantly reduced the extent of Candida morphogenesis and the rate of hyphal development. The effects of hexetidine on yeast cell viability were both concentration and time-dependent. The reduced adherence of C. albicans to BEC and the modification or inhibition of morphogenesis following exposure to hexetidine suggests a clinical role for hexetidine in the prophylaxis of both superficial candidosis and the systemic complications resulting from invasion of sub-epithelial tissue.</description><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antifungal agents</subject><subject>Antifungal Agents - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Candida albicans - drug effects</subject><subject>Candida albicans - physiology</subject><subject>Cheek</subject><subject>Epithelial Cells - drug effects</subject><subject>Epithelial Cells - microbiology</subject><subject>Female</subject><subject>Hexetidine - pharmacology</subject><subject>Humans</subject><subject>In Vitro Techniques</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Morphogenesis</subject><subject>Mouth Mucosa - drug effects</subject><subject>Mouth Mucosa - microbiology</subject><subject>Pharmacology. Drug treatments</subject><issn>0724-8741</issn><issn>1573-904X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpdkM9rFTEQx4NY6mv17EkIIsUeVjP5uc9beagtFHqp4G3JJrNuym7yTHZL_WP8X03powdP8x2-n5nvMIS8BfYJGBefL74AAw6SgQCjzAuyAWVEs2Xy50uyYYbLpjUSXpGTUu4YYy1s5TE53kolmNYb8vd2RIrDgG4pNA10xAdcgg8R6cebbCePEc9pinSpnPUjZowOH8mdjT54S-3UB2djoUui4zrbSPvVOTtR3Ic6NIUqHU5ToSHS-7DkROskxYfa3D_puv7Zm1Pej-lXjS2hvCZHg50KvjnUU_Lj29fb3WVzffP9andx3TjB2qURvVcaoNXKigFcy5UH6dnget-jbbkFEL1ynBtUmg2Ka4dysALQmdYzL07J2dPefU6_VyxLN4fyeLSNmNbSma0SRgOv4Pv_wLu05lhv6zjnWmkhTYXeHaC1n9F3-xxmm_90h6dX_8PBt6U-asg2ulCeMQ5gZA38BxfRkag</recordid><startdate>19971201</startdate><enddate>19971201</enddate><creator>JONES, D. S</creator><creator>MCGOVERN, J. G</creator><creator>WOOLFSON, A. D</creator><creator>GERMAN, S. P</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>19971201</creationdate><title>The effects of hexetidine (Oraldene) on the adherence of Candida albicans to human buccal epithelial cells in vitro and ex vivo and on in vitro morphogenesis</title><author>JONES, D. S ; MCGOVERN, J. G ; WOOLFSON, A. D ; GERMAN, S. P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c308t-3bd5611865a3f1c825d14d0fcbdbea82a113b5c227e560f526ce4fa31ec78d0d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antifungal agents</topic><topic>Antifungal Agents - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Candida albicans - drug effects</topic><topic>Candida albicans - physiology</topic><topic>Cheek</topic><topic>Epithelial Cells - drug effects</topic><topic>Epithelial Cells - microbiology</topic><topic>Female</topic><topic>Hexetidine - pharmacology</topic><topic>Humans</topic><topic>In Vitro Techniques</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Morphogenesis</topic><topic>Mouth Mucosa - drug effects</topic><topic>Mouth Mucosa - microbiology</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>JONES, D. S</creatorcontrib><creatorcontrib>MCGOVERN, J. G</creatorcontrib><creatorcontrib>WOOLFSON, A. D</creatorcontrib><creatorcontrib>GERMAN, S. P</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmaceutical research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>JONES, D. S</au><au>MCGOVERN, J. G</au><au>WOOLFSON, A. D</au><au>GERMAN, S. P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The effects of hexetidine (Oraldene) on the adherence of Candida albicans to human buccal epithelial cells in vitro and ex vivo and on in vitro morphogenesis</atitle><jtitle>Pharmaceutical research</jtitle><addtitle>Pharm Res</addtitle><date>1997-12-01</date><risdate>1997</risdate><volume>14</volume><issue>12</issue><spage>1765</spage><epage>1771</epage><pages>1765-1771</pages><issn>0724-8741</issn><eissn>1573-904X</eissn><coden>PHREEB</coden><abstract>This study reports the effects of hexetidine (Oraldene) on two virulence attributes of Candida albicans, namely, in vitro and ex vivo adherence of yeast cells to buccal epithelial cells (BEC) and in vitro morphogenesis. The effects of hexetidine treatment of either yeast cells (stationary and exponential phases) or BEC on Candidal adherence, in terms of viable and non-viable adherent yeast cells, were evaluated using an acridine orange stain in conjunction with fluorescence microscopy. Ex vivo anti-adherence effects were determined by rinsing BEC in vivo with hexetidine (0.1%), removal of BEC after defined periods and inclusion in the adherence assay. The effects of hexetidine on morphogenesis were evaluated using light microscopy. Yeast cell viability following exposure to a range of concentration of hexetidine (0.005-0.1% v/v) for defined periods was determined following serial dilution and enumeration on solid media. Treatment of stationary and exponential phase yeast cells or BEC with hexetidine (0.1%) for a range of times (10-300 s) or, alternatively, with a range of concentrations of hexetidine (0.005-0.1%) for a fixed time (30s) significantly decreased the resultant Candidal/ epithelial adhesion. No correlations were observed between reduced adherence and either time of treatment or hexetidine concentration. In vivo treatment of BEC with hexetidine (0.1%) for 30s resulted in prolonged and significant reductions in the ex vivo adherence of both viable and non-viable yeast cells for periods of up to (and including) four hours post-rinsing. Treatment of C. albicans blastospores with hexetidine (0.05, 0.1% v/v) for 10s and 30s totally inhibited Candida morphogenesis, whereas treatment with lower antiseptic concentrations significantly reduced the extent of Candida morphogenesis and the rate of hyphal development. The effects of hexetidine on yeast cell viability were both concentration and time-dependent. The reduced adherence of C. albicans to BEC and the modification or inhibition of morphogenesis following exposure to hexetidine suggests a clinical role for hexetidine in the prophylaxis of both superficial candidosis and the systemic complications resulting from invasion of sub-epithelial tissue.</abstract><cop>New York, NY</cop><pub>Springer</pub><pmid>9453066</pmid><doi>10.1023/A:1012140131757</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0724-8741
ispartof Pharmaceutical research, 1997-12, Vol.14 (12), p.1765-1771
issn 0724-8741
1573-904X
language eng
recordid cdi_proquest_miscellaneous_79537612
source MEDLINE; SpringerLink Journals - AutoHoldings
subjects Antibiotics. Antiinfectious agents. Antiparasitic agents
Antifungal agents
Antifungal Agents - pharmacology
Biological and medical sciences
Candida albicans - drug effects
Candida albicans - physiology
Cheek
Epithelial Cells - drug effects
Epithelial Cells - microbiology
Female
Hexetidine - pharmacology
Humans
In Vitro Techniques
Male
Medical sciences
Morphogenesis
Mouth Mucosa - drug effects
Mouth Mucosa - microbiology
Pharmacology. Drug treatments
title The effects of hexetidine (Oraldene) on the adherence of Candida albicans to human buccal epithelial cells in vitro and ex vivo and on in vitro morphogenesis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T14%3A56%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20effects%20of%20hexetidine%20(Oraldene)%20on%20the%20adherence%20of%20Candida%20albicans%20to%20human%20buccal%20epithelial%20cells%20in%20vitro%20and%20ex%20vivo%20and%20on%20in%20vitro%20morphogenesis&rft.jtitle=Pharmaceutical%20research&rft.au=JONES,%20D.%20S&rft.date=1997-12-01&rft.volume=14&rft.issue=12&rft.spage=1765&rft.epage=1771&rft.pages=1765-1771&rft.issn=0724-8741&rft.eissn=1573-904X&rft.coden=PHREEB&rft_id=info:doi/10.1023/A:1012140131757&rft_dat=%3Cproquest_pubme%3E516535521%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=222656347&rft_id=info:pmid/9453066&rfr_iscdi=true